SCHEMBL1958044

SCHEMBL1958044

COC(=O)c1ccc(F)cc1Oc1ccc(F)c2c1cnn2COCC[Si](C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 4/20 0.37
▸ MAPK14 Q16539 1/20 0.35
▸ FFAR4 Q5NUL3 1/20 0.35
▸ F2RL1 P55085 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CCR1 P32246 1/20 0.33
▸ SCN8A Q9UQD0 1/20 0.32
▸ SCN10A Q9Y5Y9 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ SCN9A Q15858 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1957574 0.85 DGAT1 (0.36) DGAT1MAPK14FFAR4F2RL1TSHR
SCHEMBL31638952 0.77 ROCK2 (0.41) TSHRALDH1A1HPGDMAPTCCR1
SCHEMBL31638929 0.77 ROCK2 (0.41) TSHRALDH1A1HPGDCCR1KMT2A
SCHEMBL1958349 0.76 BCL2 (0.50) —
SCHEMBL1958266 0.76 FGFR1 (0.39) DGAT1FFAR4TSHRALDH1A1MAPT
SCHEMBL31211006 0.74 KMT2A (0.38) DGAT1F2RL1TSHRHSD17B10MAPT
SCHEMBL31019222 0.74 DGAT1 (0.36) DGAT1FFAR4ALDH1A1HPGDHSD17B10
SCHEMBL29246322 0.74 DGAT1 (0.36) DGAT1FFAR4ALDH1A1HPGDHSD17B10
SCHEMBL31638853 0.73 DGAT1 (0.36) DGAT1F2RL1TSHRALDH1A1HPGD
SCHEMBL1957623 0.73 F2RL1 (0.39) DGAT1F2RL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029404-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2015-05-12 — — US disclosed
EP-2507211-B1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2014-06-18 — — EP disclosed
US-20140088106-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2014-03-27 — — US disclosed
US-8557983-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2013-10-15 — — US disclosed
EP-2507211-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 — — EP disclosed
WO-2011068560-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
US-20100298323-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298323-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 DGAT1 1925/4885MAPK14 1254/4885FFAR4 3784/4885
US-20140088106-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 DGAT1 1925/4885MAPK14 1254/4885FFAR4 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback